COMP <GO>
TWST vs KYMR // OPTIONS IMPLIED MOVE & PUT/CALL SKEW
Twist Bioscience Corporation (NASDAQ) VS. Kymera Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: TWST 7
— KYMR 3
■ METRIC PARITY
LAST: $129.04 (-15.54%) • MKT CAP: $10.13B
options-implied-move
—
LAST: $127.51 (+0.70%) • MKT CAP: $10.81B
options-implied-move
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TWST VS. KYMR)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | TWST | KYMR | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 94.20% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -11.70% | -21.40% | +9.70 | TWST | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -0.66% | -2.30% | +1.64 | TWST | /fcf-yield <GO> |
| Operating Margin | -4.20% | -60.00% | +55.80 | TWST | /operating-margins <GO> |
| Net Profit Margin | -2.40% | 68.00% | -70.40 | KYMR | /net-margins <GO> |
| Revenue Growth (YoY) | 16.50% | -16.70% | +33.20 | TWST | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 26.00 | 0.00 | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 4/9 | +2.00 | TWST | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew ACTIVE | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 48.4 | 66.0 | -17.60 | KYMR | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.98 | 0.95 | +0.03 | TWST | /macro-sensitivity <GO> |
| Forward P/E Multiple | 21.0x | 30.4x | -9.40 | TWST | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $10.13B | $10.81B | -$681.1M | KYMR | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | TWST REV | KYMR REV | TWST GROSS % | KYMR GROSS % | TWST FCF | KYMR FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $381.5M | $39.2M | — | 0.0% | -$75.6M | -$234.3M |
| FY 2024 | $618.3M | $47.1M | — | 0.0% | -$69.2M | -$207.3M |
| FY 2023 | $608.0M | $78.6M | — | — | -$142.5M | -$106.4M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TWST // BETA 0.98
KYMR // BETA 0.95